DK1163224T3 - N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens - Google Patents

N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens

Info

Publication number
DK1163224T3
DK1163224T3 DK00909542T DK00909542T DK1163224T3 DK 1163224 T3 DK1163224 T3 DK 1163224T3 DK 00909542 T DK00909542 T DK 00909542T DK 00909542 T DK00909542 T DK 00909542T DK 1163224 T3 DK1163224 T3 DK 1163224T3
Authority
DK
Denmark
Prior art keywords
insulin resistance
propoxy
pyridine
hydroxy
oxide
Prior art date
Application number
DK00909542T
Other languages
Danish (da)
English (en)
Inventor
Maria Kuerthy
Laszlo Ueroegdi
Magdolna Toeroek
Mihalyne Kardos
Zoltan Nagy
Katalin Biro
Karoly Nagy
Zita Csakai
Jeno Szilbereky
Tamas Mogyorosi
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Application granted granted Critical
Publication of DK1163224T3 publication Critical patent/DK1163224T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00909542T 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens DK1163224T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
DK1163224T3 true DK1163224T3 (da) 2003-08-04

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909542T DK1163224T3 (da) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens

Country Status (27)

Country Link
US (1) US6649628B1 (ja)
EP (1) EP1163224B1 (ja)
JP (1) JP4689838B2 (ja)
KR (1) KR100676124B1 (ja)
AT (1) ATE237590T1 (ja)
AU (1) AU779096B2 (ja)
BG (1) BG65178B1 (ja)
BR (1) BR0008969A (ja)
CA (1) CA2360451C (ja)
CZ (1) CZ297386B6 (ja)
DE (1) DE60002187T2 (ja)
DK (1) DK1163224T3 (ja)
EE (1) EE04961B1 (ja)
ES (1) ES2193055T3 (ja)
HR (1) HRP20010584B1 (ja)
HU (1) HUP9900475D0 (ja)
IL (2) IL144866A0 (ja)
NO (1) NO319793B1 (ja)
PL (1) PL197692B1 (ja)
PT (1) PT1163224E (ja)
RS (1) RS50083B (ja)
RU (1) RU2250901C2 (ja)
SI (1) SI1163224T1 (ja)
SK (1) SK287063B6 (ja)
UA (1) UA72495C2 (ja)
WO (1) WO2000050403A1 (ja)
ZA (1) ZA200106488B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
AU2003202104B8 (en) * 2002-01-11 2008-10-02 Cytrx Corporation Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
EP2356988A4 (en) * 2008-11-18 2012-05-09 Santen Pharmaceutical Co Ltd THERAPEUTIC FOR CHORIORETINAL DEGENERATION WITH PYRIDINE-3-CARBALDEHYDE O- (PIPERIDIN-1-YL-PROPYL) OXIM DERIVATIVE AS ACTIVE SUBSTANCE
PT2646044T (pt) 2010-11-30 2019-11-12 Orphazyme As Métodos para aumentar a atividade intracelular de hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
US9861654B2 (en) * 2012-09-06 2018-01-09 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
HUE034782T2 (en) 2012-09-14 2018-02-28 Saint Gobain Shield with electrical connector
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PT3193840T (pt) * 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
CA3063974A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
MX2020012480A (es) 2018-05-28 2021-03-25 Orphazyme As Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
EP4171559A1 (en) 2020-06-24 2023-05-03 Zevra Denmark A/S Arimoclomol for treating gaucher disease
EP4247792A1 (en) * 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2022136640A1 (en) 2020-12-24 2022-06-30 Orphazyme A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
ES2193055T3 (es) 2003-11-01
EP1163224A1 (en) 2001-12-19
NO20014103D0 (no) 2001-08-23
IL144866A0 (en) 2002-06-30
ZA200106488B (en) 2002-08-07
CA2360451A1 (en) 2000-08-31
WO2000050403A1 (en) 2000-08-31
CA2360451C (en) 2011-01-04
BG65178B1 (bg) 2007-05-31
NO20014103L (no) 2001-10-22
EP1163224B1 (en) 2003-04-16
SK11582001A3 (sk) 2001-12-03
HUP9900475D0 (en) 1999-04-28
NO319793B1 (no) 2005-09-12
SK287063B6 (sk) 2009-10-07
AU779096B2 (en) 2005-01-06
JP4689838B2 (ja) 2011-05-25
HRP20010584A2 (en) 2002-08-31
PL197692B1 (pl) 2008-04-30
CZ20013053A3 (cs) 2002-01-16
DE60002187T2 (de) 2003-12-11
UA72495C2 (uk) 2005-03-15
HRP20010584B1 (en) 2010-08-31
CZ297386B6 (cs) 2006-11-15
IL144866A (en) 2007-07-04
AU3182400A (en) 2000-09-14
ATE237590T1 (de) 2003-05-15
PT1163224E (pt) 2003-07-31
PL350915A1 (en) 2003-02-10
RS50083B (sr) 2009-01-22
RU2250901C2 (ru) 2005-04-27
YU60301A (sh) 2004-05-12
JP2002537384A (ja) 2002-11-05
DE60002187D1 (de) 2003-05-22
BR0008969A (pt) 2001-11-27
BG105837A (en) 2002-03-29
KR100676124B1 (ko) 2007-01-31
EE04961B1 (et) 2008-02-15
SI1163224T1 (en) 2003-08-31
EE200100447A (et) 2002-12-16
KR20010102410A (ko) 2001-11-15
US6649628B1 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
DK1163224T3 (da) N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
CY1106409T1 (el) Παραγωγα κινολινης
MA27649A1 (fr) Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci.
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
NO20024291L (no) Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
TR200200987T2 (tr) Kanser tedavisine yönelik,ornatılmış pirroller
DK1232173T3 (da) Nye fusidinsyrederivater
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
IL172675A0 (en) Benzofuran derivatives and their use in the treatment of microbial infections
IL165996A0 (en) Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use